LivaNova to Announce Third-Quarter 2025 Results

Audio By Carbonatix

LONDON--(BUSINESS WIRE)--Oct 8, 2025--

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2025 results on Wed., Nov. 5, 2025, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2025 results prior to the call.

The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 817099. A replay will be available on the Investors section of the LivaNova website immediately following the event.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the next Company conference call. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251008663687/en/

CONTACT: LivaNova Investor Relations and Media Contacts+1 281-895-2382

Briana Gotlin

VP, Investor Relations

[email protected] Wilke

VP, Corporate Communications

[email protected]

KEYWORD: NORTH AMERICA UNITED STATES IRELAND UNITED KINGDOM EUROPE

INDUSTRY KEYWORD: RESEARCH GENERAL HEALTH MENTAL HEALTH MEDICAL DEVICES HOSPITALS HEALTH TECHNOLOGY SURGERY CLINICAL TRIALS SCIENCE CARDIOLOGY BIOTECHNOLOGY FDA HEALTH

SOURCE: LivaNova PLC

Copyright Business Wire 2025.

PUB: 10/08/2025 09:00 AM/DISC: 10/08/2025 08:59 AM

http://www.businesswire.com/news/home/20251008663687/en